PET Imaging Quantifying <sup>68</sup>Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer.
Where this comes from
- Record sourced from PubMed, PMID 32358088.
- Also identified by DOI 10.2967/jnumed.119.233312.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as <sup>177</sup>Lu-PSMA-617, is used to treat metastatic prostate cancer. <sup>177</sup>Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed <sup>68</sup>Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for <sup>177</sup>Lu-PSMA-617 PRRT.
Medical subject headings
- Colorectal Neoplasms
- Edetic Acid
- Oligopeptides
- Positron-Emission Tomography
- Radiopharmaceuticals